Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

Mangoceuticals announced that its subsidiary MangoRx IP Holdings has secured $2.5 million in strategic investment from two investors for a 25% membership interest. The initial $1.75 million tranche has been received, with the remaining $750,000 due by November 28, 2026. The investment will fund commercialization of the company's antiviral intellectual property portfolio covering oral-surface administered preparations, with potential applications in poultry, livestock, and human oral-care markets valued at approximately $74.6 billion combined.